The WT1 gene - Its role in tumourigenesis and prospects for immunotherapeutic advances

In Vivo

Volumn 28, Issue 5, 2014, Pages 675-682

  Lindstedt, Ingrid ^a   Lindgren, Michelle Alexius ^a   Andersson, Erika ^a   Engström, Wilhelm ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Review; Tumourigenesis; Vaccine; Wilms' tumour; WT1

Indexed keywords

CANCER VACCINE; WT1 PROTEIN;

CARCINOGENESIS; DENYS DRASH SYNDROME; DOSE RESPONSE; DRUG EFFICACY; GENE FUNCTION; GENE STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LEUKEMIA; LUNG CANCER; NEPHROBLASTOMA; NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SPERMATOGENESIS; TUMOR GENE; TUMOR SUPPRESSOR GENE; ANIMAL; CELL TRANSFORMATION; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; CANCER VACCINES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; WT1 PROTEINS;

EID: 84918578038     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Wilms MI: Die Mischgeschwülste. In: Die Mischgeschwülste der Niere. Leipzig, A Georgi, 1899.
2. Huff V and Saunders GF: Wilms' tumour genes. Biochim Biophys Acta 1155: 295-306, 1993.
3. Engström W and Granerus M: The expression of the insulin-like growth factor II, JIP1 and WT1 genes in porcine nephroblastoma. Anticancer Res 12: 4999-5003, 2009.
4. Sugiyama H: WT1 (Wilms' tumour gene 1): Biology and cancer immunotherapy. Jpn J Clin Oncol 5: 377-387, 2010.
5. Ozdemir DD and Hohenstein P: Wt1 in the kidney-A tale in mouse models. Pediatric Nephrology 4: 687-693, 2014.
6. Hohenstein P and Hastie ND: The many facets of the Wilms' tumour gene, WT1. Human Molecular Genetics 2: 196-201, 2006.
7. Royer-Pokora B: Genetics of paediatric renal tumours. Paediatric Nephrology 1: 13-23, 2013.
8. Dudnakova T, Spraggon L, Slight J and Hastie N: Actin: a novel interaction partner of WT1 influencing its cell dynamic properties. Oncogene 29: 1085-1092, 2010.
9. Essafi A, Webb A, Berry RL, Slight J, Burn SF, Spraggon L, Velecela V, Martinez-Estrada OM, Wiltshire JH, Roberts SGE, Brownstein D, Davies JA, Hastie ND and Hohenstein PA: Wt1- controlled chromatin switching mechanism underpins tissuespecific Wnt4 activation and repression. Developmental Cell 3: 559-574, 2011.
10. Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heyningen V and Hastie ND: Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 3: 391-401, 1995.
11. Wang X, Gao P, Lin F, Long M, Weng Y, Ouyang Y, Liu L, Wei J, Che X, He T, Zhang H and Dong K: Wilms' tumour suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/AKT pathway. Cancer Cell International 13: 114, 2013.
12. Zheng QS, Wang XN, Wen Q, Zang Y, Chen SR, Zhang J, Li,XX, Sha RN, Hu ZY, Gao F and Liu YX: WT1 deficiency causes undifferentiated spermatogonia accumulation and meiotic progression disruption in neonatal mice. Reproduction 147: 45-52. 2014.
13. Patek CE, Brownstein DG, Fleming S, Wroe C, Rose L, Webb A, Berry RL, Devenney PS, Walker M, Maddocks ODK, Lawrence NJ, Harrison DJ, Wood KM, Miles CG and Hooper ML: Effects on kidney disease, fertility and development in mice inheriting a protein-truncating Denys-Drash syndrome allele (Wt1 tmT396). Transgenic Research 17: 459-475, 2007.
14. Caignec CL, Delnatte C, Vermeesch JR, Boceno M, Joubert M, Lavenant F, David A and Rival,JM: Complete Sex Reversal in a WAGR Syndrome Patient. Am J Med Geneti 143A: 2692-2695, 2007.
15. Gwin K. Cajaiba MM, Caminoa-Lizarralde A, Picazo ML, Nistal M and Reyes-Múgica MM Expanding the clinical spectrum of Frasier syndrome. Paediatric and Dev Pathol 11: 122-127, 2008.
16. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D and Jaenisch R: WT-1 is required for early kidney development. Cell 4: 679-691, 1993.
17. Royer-Pokora B, Weirich A, Schumacher V, Uschkereit C, Beier M, Leuschner I, Graf N, Autschbach F, Schneider D and von Harrach M: Clinical relevance of mutations in the Wilms tumour suppressor 1 gene WT1 and the cadherin associated protein beta 1 gene CTNNB1 for patients with Wilms tumours. Cancer 113: 1080-1089, 2008.
18. Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong L, Behringer R and Huff V: WT1 ablation and Igf2 up-regulation in mice result in Wilms' tumors with elevated ERK1/2 phosphorylation. J Clin Invest 1: 174-183, 2011.
19. Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, Inoue M, Mori M, Nakatsuka S, Sakaguchi N, Miyazaki K, Nakamura M, Fukuda I, Nakamura J. Tatsumi N, Takakuwa T, Nishida S, Shirakata T, Hosen N, Tsuboi A, Nezu R, Maeda H, Oka,Y, Kawase I, Aozasa K, Okumura M, Miyoshi S and Sugiyama H: WT1 IgG antibody for early detection of non-small cell lung cancer and as its prognostic factor. Int J Cancer 2: 381-387, 2009.
20. Inoue, K, Sugiyama H, Ogawa, H, Nakagawa M, Yamagami T, Miwa H Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi, H, Ishidate T, Akiyama T and Kishimoto T: WTI as a New Prognostic Factor and a New Marker for the Detection of Minimal Residual Disease in Acute Leukaemia. Blood 84: 3071-3079, 1993.
21. Cillioni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferraro D, Galliami A, Levis A, Saglio G: Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes. J Clin Oncology 10: 1988-1995, 2003.
22. Bourkoula K, Englert C, Giais, M, Köhler R, Krammer PH and Li-Weber M: The Wilms' tumour suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells. Int J Cancer 134: 291-300, 2013.
23. Chen L, Park SM, Tumanov AV. Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E and Peter ME: CD95 promotes tumour growth. Nature 465: 492-496, 2010.
24. Van Driessche A, Berneman ZN and van Tendeloo VFI: Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumours: Lessons from Early Clinical Trials. The Oncologist 17: 250-259, 2012.
25. Oka Y, Tsuboi, A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I and Sugiyama H: Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt Leukaemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis. Int J Hematology 78: 56-61, 2003.
26. Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y and Sugiyama H: Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 13: 2345-2352, 2006.
27. Ohminami H, Yasukawa M and Fujita S: HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. J Am Soc Hematology 1: 286-293, 2000.
28. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida, S, Shirakata T, Ohno S, Oji Y, Aozasa, K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase, I, Nakatsuka SI, Sugiyama H, Sakamoto JA: Phase I/II Trial of a WT1 (Wilms' Tumour Gene) Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I Data. Jap J Clin Oncol 36: 231-236, 2006.
29. Soeda A, Morita-Hoshi Y, Kaida M, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T and Heike Y: Long-Term Administration of Wilms Tumour-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites. Jap J Clin Oncol 40: 1184-1188, 2010.
30. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Wolfgang Blau I, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. J Am Soc Hematol 26: 6541-6548, 2009.
31. Van Tendelooa VF, Van de Veldea A, Van Driesschea A, Coolsa N, Anguillea S, Ladellb K, Gostickb E, Vermeulena K, Pietersa K, Nijsa G, Steina B, Smitsa EL, Schroyensa WA, Gadisseura AP, Vrelusta I, Jorensa PG, Goossensa H, de Vriesc IJ, Priceb DA, Ojid Y, Okad Y, Sugiyama H and Bernemana ZN: Induction of complete and molecular remissions in acute myeloid leukaemia by Wilms' tumour 1 antigen-targeted dendritic cell vaccination. Proc Nat Acad Sci (USA) 31: 13824-13829, 2010.
32. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin, J, Van Calenbergh, F, Menten, J, Clement, P, Debiec-Rychter M and De Vleeschouwer S: Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Imm Immunother 61: 2033-2044, 2012.
33. European Medicines Agency, EU Clinical Trials Register https:// www.clinicaltrialsregister.eu/ctr-search/search?query=DCM (2014-03-13).
34. Izumoto S Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto, N, Elisseeva OA, Shirakata, T, Kawakami M, Oji Y, Nishida S, Ohno, S, Kawase I, Hatazawa J, Nakatsuka SI, Aozasa K, Morita S, Sakamoto J, Sugiyama H and Yoshimine, T: Phase II clinical trial of Wilms tumour 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurgery 5: 963-971, 2008.
35. Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi, A, Oji, Y, Hosen N, Nakatsuka S, Morita S, Sakamoto J, Sugiyama H and Kimura T: WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. J Cancer Res Clin Oncol 13: 457-463, 2012.
36. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto KI, Morita S, Sakamoto JI. Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H and Inoue M: Wilms' Tumor 1 (WT1) Peptide Immunotherapy for Gynecological Malignancy. Anticancer Res 11: 4779-4784, 2009.
37. Asai H, Fujiwara H, Kitazawa S, Kobayashi N, Ochi T, Miyazaki Y, Ochi F, Akatsuka Y, Okamoto S, Mineno J, Kuzushima K. Ikeda H, Shiku H and Yasukawa M: Adoptive transfer of genetically engineered WT1-specific cytotoxicity T lymphocytes does not induce renal injury. J Hematol Oncol 7: 3, 2014.
38. Busse, A, Letsch A, Scheibenbogen C, Nonnenmacher A, Ochsenreither S, Thiel, E and Keilholz U: Mutation or loss of Wilms' tumour gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination. J Translat Med 8: 5, 2010.
39. Rezvani K, Yong ASM, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R and Barrett AJ: Repeated PR1 and WT1 peptide vaccination in Montanide-Adjuvant fails to induce sustained high-Avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematology 3: 432-440, 2011.
40. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DE and Housman D: Expression of the Wilms tumour gene WT1 in the murine urogenital system. Genes Dev 5: 1345-1356, 1991.
41. Rein LA and Chao NJ: WT1 vaccination in acute myeloid leukaemia. New methods of implementing adoptive immunotherapy. Exp Op Investig Drugs 23: 417-426, 2014.